Loading…
Disclosed for 38 months, Aug 2023 to Sep 2026.
quant Healthcare Fund is an active equity fund in the Sectoral / Thematic category from quant Mutual Fund. In September 2026 it disclosed 16 stocks worth ₹425 Cr, down ₹3.8 Cr from Aug 2026. Its largest positions were GlaxoSmithKline Pharmaceuticals Limited (9.7%), Divi's Laboratories Limited (9.6%), Aurobindo Pharma Limited (9.6%); the ten largest together made up 84.9% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 81.7% of its equity. Cash and debt stood at 0.6%. Compared with Aug 2026 the fund entered 7 new stocks and exited 2.
Top-10 weight is higher than 99% of peers
Holds more stocks than 3% of peers
Holds more cash than 8% of peers
What these mean: concentration · cash
Every line the fund disclosed, with the change against Aug 2026. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| GlaxoSmithKline Pharmaceuticals Limited | 9.69% | down 0.89 pts | ₹41.1 Cr | down ₹4.2 Cr | Trimmed |
| Divi's Laboratories Limited | 9.63% | up 9.63 pts | ₹40.9 Cr | up ₹40.9 Cr | New |
| Aurobindo Pharma Limited | 9.61% | up 4.43 pts | ₹40.8 Cr | up ₹18.6 Cr | Added |
| Zydus Lifesciences Limited | 9.39% | up 0.09 pts | ₹39.8 Cr | up ₹2 L | Held |
| Glenmark Pharmaceuticals Limited | 9.34% | up 9.34 pts | ₹39.6 Cr | up ₹39.6 Cr | New |
| Strides Pharma Science Limited | 9.04% | up 6.59 pts | ₹38.4 Cr | up ₹27.9 Cr | Added |
| Torrent Pharmaceuticals Limited | 8.62% | up 8.62 pts | ₹36.6 Cr | up ₹36.6 Cr | New |
| Pfizer Limited | 7.37% | down 1.46 pts | ₹31.3 Cr | down ₹6.5 Cr | Trimmed |
| Glenmark Life Sciences Limited | 6.21% | down 1.87 pts | ₹26.4 Cr | down ₹8.2 Cr | Trimmed |
| IPCA Laboratories Limited | 5.98% | down 0.24 pts | ₹25.4 Cr | down ₹1.2 Cr | Trimmed |
| Zydus Wellness Limited | 4.90% | down 0.75 pts | ₹20.8 Cr | down ₹3.4 Cr | Trimmed |
| Colgate Palmolive (India) Limited | 3.45% | up 3.45 pts | ₹14.6 Cr | up ₹14.6 Cr | New |
| Natco Pharma Limited | 3.01% | up 3.01 pts | ₹12.8 Cr | up ₹12.8 Cr | New |
| Dr. Reddy's Laboratories Limited | 2.33% | up 2.33 pts | ₹9.9 Cr | up ₹9.9 Cr | New |
| 91 Days Treasury Bill 15-Oct-2026 Debt | 0.71% | up 0.01 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 22-Oct-2026 Debt | 0.70% | up 0.01 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 05-Nov-2026 Debt | 0.70% | up 0.01 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 19-Nov-2026 Debt | 0.70% | up 0.01 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 27-Nov-2026 Debt | 0.70% | up 0.01 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 03-Dec-2026 Debt | 0.70% | up 0.70 pts | ₹3 Cr | up ₹3 Cr | New |
| 91 Days Treasury Bill 10-Dec-2026 Debt | 0.70% | up 0.70 pts | ₹3 Cr | up ₹3 Cr | New |
| 91 Days Treasury Bill 17-Dec-2026 Debt | 0.70% | up 0.70 pts | ₹3 Cr | up ₹3 Cr | New |
| 91 Days Treasury Bill 24-Dec-2026 Debt | 0.70% | up 0.70 pts | ₹3 Cr | up ₹3 Cr | New |
| LG Electronics India Ltd | 0.59% | up 0.59 pts | ₹2.5 Cr | up ₹2.5 Cr | New |
| Sumitomo Chemical India Limited | 0.26% | down 0.05 pts | ₹1.1 Cr | down ₹21 L | Trimmed |
| Cash, TREPS & receivables | −5.73% | down 1.18 pts | −₹24.3 Cr | down ₹4.8 Cr | Trimmed |
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Compared with
Since Aug 2026, the weight rose most in Pharmaceuticals (+5.6 pts) and Personal Products (+3.5 pts), and fell most in Pharmaceuticals & Biotechnology (−6.4 pts) and Food Products (−3.1 pts).
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
| Sector | Sep 2023 | Sep 2025 | Mar 2026 | Jun 2026 | Aug 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 50.1% | 70.7% | 63.6% | 52.1% | 88.1% | 81.7% |
| Pharmaceuticals | 8.1% | — | — | 4.0% | 3.5% | 9.1% |
| Food Products | — | 9.4% | 9.9% | 13.3% | 8.0% | 4.9% |
| Personal Products | — | — | — | — | — | 3.5% |
| Consumer Durables | — | — | — | — | — | 0.6% |
| Fertilizers & Agrochemicals | — | — | — | — | 0.4% | 0.3% |
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
| 5.0% |
| 378% |
| Apr 2026 | ₹352 Cr | 15 | 2 | 2 | 5.1% | 11.0% | 366% |
| Mar 2026 | ₹327 Cr | 15 | 1 | 1 | −6.6% | 0.1% | 353% |
| Feb 2026 | ₹350 Cr | 15 | 4 | 2 | −5.6% | 0.6% | 338% |
| Jan 2026 | ₹341 Cr | 13 | 1 | 3 | −0.4% | 3.7% | 307% |
| Dec 2025 | ₹362 Cr | 15 | 3 | 2 | −5.4% | 0.7% | 285% |
| Nov 2025 | ₹379 Cr | 14 | 0 | 1 | −3.3% | 4.4% | 254% |
| Oct 2025 | ₹384 Cr | 15 | 3 | 2 | −3.7% | 2.6% | 226% |
| Sep 2025 | ₹379 Cr | 14 | 0 | 2 | 1.2% | 5.4% | 169% |
| Aug 2025 | ₹384 Cr | 16 | 2 | 1 | −3.0% | 1.4% | 177% |
| Jul 2025 | ₹409 Cr | 15 | 2 | 2 | −3.9% | 0.7% | 175% |
| Jun 2025 | ₹425 Cr | 15 | 0 | 0 | −2.4% | 3.2% | 163% |
| May 2025 | ₹417 Cr | 15 | 3 | 2 | −2.9% | 0.2% | 157% |
| Apr 2025 | ₹396 Cr | 14 | 1 | 2 | −0.3% | 0.9% | 148% |
| Mar 2025 | ₹370 Cr | 15 | 0 | 0 | −2.1% | 0.6% | 145% |
| Feb 2025 | ₹348 Cr | 15 | 0 | 0 | −1.9% | 0.9% | 156% |
| Jan 2025 | ₹402 Cr | 15 | 1 | 7 | −1.8% | 1.9% | 181% |
| Dec 2024 | ₹424 Cr | 21 | 0 | 0 | −0.3% | 0.9% | 190% |
| Nov 2024 | ₹440 Cr | 21 | 1 | 1 | −0.1% | 1.0% | 223% |
| Oct 2024 | ₹437 Cr | 21 | 3 | 0 | 1.2% | 1.2% | 249% |
For any of the 14 earlier months, choose it in “Portfolio as of” at the top of the page.